Boris Pasche (hs0379)
University information
Contact information
Oncology
Chair & Professor
Department of Oncology
School of Medicine
President & CEO
Karmanos Cancer Institute
Karmanos Cancer Institute
Hudson-Webber Cancer Research Center
4100 John R.
Detroit, MI 48201
Karmanos Cancer Institute
4100 John R., HW02EA
Detroit, MI 48201
313-576-8760
Dr. Pasche’s career spans over 30 years, in which he’s held numerous executive leadership positions. He has shown great success in growing and expanding an NCI-designated comprehensive cancer center’s program resulting in more funding, and has strengthened and re-organized cancer research programs leading to NCI core grant renewal. Dr. Pasche is an elected member of the American Society for Clinical Investigation and the American Clinical and Climatological Association. He is the recipient of Ohio State University Human Cancer Genetics Program Commemorative Medal and the Jeanik M. Littelfield-American Association for Cancer Research Award in Metastatic Colon Cancer Research. Dr. Pasche is a member of the American Association of Cancer Research, American Association of Clinical Oncology, American Society of Hematology, American Society of Human Genetics, The Bioelectromagnetics Society, and the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group. He also served as an associate editor for JAMA (Journal for American Medical Association), a peer-reviewed medical journal, for over a decade.
Education
(1986) MD, Karolinska Institute, Solna, Sweden
(1987) MD, University of Lausanne, Lausanne, Switzerland
(1989) PhD, Karolinska Institute, Solna, Sweden
Postgraduate Training
(1989-1992) Research fellow in the laboratory of Dr. Joseph Loscalzo, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School. Boston, MA
(1996-2000) Research fellow in the laboratory of Dr. Joan Massagué, Cell Biology Program, Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research. New York, NY
Graduate Medical Training
(1992-1994) Internship and Residency in Medicine, The New York Hospital Cornell Medical Center. New York, NY
(1994-1997) Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center and the New York Hospital, Cornell University Medical College. New York, NY
Faculty Appointments:
(2023-Present) Professor and Chair, Department of Oncology, Wayne State University School of Medicine, Detroit, MI
(2014-2022) Professor and Chair, Department of Cancer Biology, Wake Forest University. Winston-Salem, NC
(2008-2014) Professor of Medicine with tenure and Director, Division of Hematology/Oncology, The University of Alabama at Birmingham, Birmingham, AL
(2006-2008) Associate Professor of Medicine, Northwestern University Medical School, Chicago, IL
(2001-2005) Assistant Professor of Medicine, Northwestern University Medical School, Chicago, IL
Hospital or Other Professional Appointments:
(2023-Present) Center Director, Barbara Ann Karmanos Cancer Center, Detroit, MI
(2014-2022) Director, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC
(2009-2014) Deputy Director, University of Alabama Comprehensive Cancer Center, Birmingham, AL
(2008-2009) Associate Director for Translational Research, The University of Alabama Comprehensive Cancer Center, Birmingham, AL
(2006-2008) Co-leader then Leader, Cancer Genes and Molecular Targeting Program, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
(2002-2008) Founder and Director, Northwestern University Cancer Genetics Program, Chicago, IL
The American College of Physicians (ACP)
The American Society of Internal Medicine (ASIM)
The American Society for Clinical Investigation (ASCI)
The American Clinical and Climatological Association (ACCA)
The American Society of Hematology (ASH)
The American Society of Clinical Oncology (ASCO)
The American Association for Cancer Research (AACR)
The American Society of Human Genetics (ASHG)
The Bioelectromagnetics Society (BEMS)
As an experienced hematologist and medical oncologist, Dr. Pasche’s clinical specialties are in treating gastrointestinal malignancies and hereditary cancer. His research focuses on cancer susceptibility and new therapies. In 2023, a medical device Dr. Pasche co-invented, TheraBionic P1, was approved by the FDA for the treatment of advanced hepatocellular carcinoma, the most common type of liver cancer.
School of Medicine
Karmanos Cancer Institute
Hudson-Webber Cancer Research Center
4100 John R.
Detroit, MI 48201
313-576-8760
Dr. Pasche’s career spans over 30 years, in which he’s held numerous executive leadership positions. He has shown great success in growing and expanding an NCI-designated comprehensive cancer center’s program resulting in more funding, and has strengthened and re-organized cancer research programs leading to NCI core grant renewal. Dr. Pasche is an elected member of the American Society for Clinical Investigation and the American Clinical and Climatological Association. He is the recipient of Ohio State University Human Cancer Genetics Program Commemorative Medal and the Jeanik M. Littelfield-American Association for Cancer Research Award in Metastatic Colon Cancer Research. Dr. Pasche is a member of the American Association of Cancer Research, American Association of Clinical Oncology, American Society of Hematology, American Society of Human Genetics, The Bioelectromagnetics Society, and the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group. He also served as an associate editor for JAMA (Journal for American Medical Association), a peer-reviewed medical journal, for over a decade.
Education
(1986) MD, Karolinska Institute, Solna, Sweden
(1987) MD, University of Lausanne, Lausanne, Switzerland
(1989) PhD, Karolinska Institute, Solna, Sweden
Postgraduate Training
(1989-1992) Research fellow in the laboratory of Dr. Joseph Loscalzo, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School. Boston, MA
(1996-2000) Research fellow in the laboratory of Dr. Joan Massagué, Cell Biology Program, Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research. New York, NY
Graduate Medical Training
(1992-1994) Internship and Residency in Medicine, The New York Hospital Cornell Medical Center. New York, NY
(1994-1997) Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center and the New York Hospital, Cornell University Medical College. New York, NY
As an experienced hematologist and medical oncologist, Dr. Pasche’s clinical specialties are in treating gastrointestinal malignancies and hereditary cancer. His research focuses on cancer susceptibility and new therapies. In 2023, a medical device Dr. Pasche co-invented, TheraBionic P1, was approved by the FDA for the treatment of advanced hepatocellular carcinoma, the most common type of liver cancer.
